Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

α-Diazo N-heteroarenium salts: synthesis and reactivity of a novel

class of 'Onium' diazo compounds

Ya-Xi Li, Quan-Yun Liu, Yi Zhang, Miao-Miao Liu, Xiaoqian Liu, Mei-Hua Shen*, Fang-Ming Wang and Hua-Dong Xu*

Supporting Information

Contents

I. General information and materials	1
II. Preparation and characterization of substrates	2
III. N-alkylation of substrates 1	6
IV. Transformations of α-N-heteroaryldiazoalkane tetrafluoroborates enabled by	
Rhodium catalysis	.11
V. Reduction reaction of product 5, 6, 9	.20
VI. References	.24
VII. ¹ H and ¹³ C NMR spectra of compounds	.25

I. General information and materials

NMR spectra were recorded using Bruker AV - 300 / AV- 400 spectrometers. The data are reported as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration. High resolution mass spectra were acquired by the Shanghai Institute of Organic Chemistry National Center for Organic Mass Spectrometry in China on a Thermo Fisher Scientific LTQ FT Ulta. Analytical thin layer chromatography was performed on 0.25 mm extra hard silica gel plates with UV254 fluorescent indicator and/or by exposure to phosphormolybdic acid/cerium (IV) sulfate/ ninhydrine followed by brief heating with a heat gun. Liquid chromatography (flash chromatography) was performed on 60Å (40 – 60 μ m) mesh silica gel (SiO2). All reactions were carried out under nitrogen or argon with anhydrous solvents in ovendried glassware, unless otherwise noted. All reagents were commercially obtained and, where appropriate, purified prior to use.

II. Preparation and characterization of substrates

S1a-S1d, S1h-S1i are commercially available.


S1e-S1g were obtained following literature protocols. ¹

A. General procedure for the preparation of ethyl N-heteroaryleacetate S2

LDA
$$\begin{array}{c}
 & \text{Diethyl carbonate} \\
 & \text{N} & \text{Diethyl carbonate} \\
 & \text{THF,-78°C - rt} \\
 & \text{overnight}
\end{array}$$
S1a, S1d, S1e, S1g-S1i
S2a, S2d, S2e, S2g-S2i

S2a, S2d, S2e, S2g-S2i were obtained following the method reported by Richard Frenette and co-workers.² To a 100 mL Schlenk flask, diisopropylamine (5.6 mL, 40.0 mmol) and THF (30 mL) were added and cooled to -78° C. Butyllithium (14.4 mL, 36.0 mmol) (2.5M in hexane) was then added dropwise and the mixture was stirred for 30 minutes. The solution of methyl-substituted N-heterocyclic compound (20.0 mmol) in 10 mL THF was added, and the mixture was stirred for 1 h. Diethyl carbonate (4.8 mL, 40.0 mmol) was added, and the mixture was stirred at -78° C overnight when temperature was slowly raised to ambient temperature. The reaction was quenched with the aq. NH₄Cl and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude oil was purified by flash column chromatography on silica gel using petroleum ether/ethylacetate (PE: EA = 5:1) as an eluent to afford S2a, S2d, S2e, S2g-S2i in 46~86% yields.

B. General procedure for preparation of t-butyl N-heteroaryleacetate S2



S2b, **S2c**, **S2f** were obtained following the method reported by Richard Frenette and co-workers. ²To a 100 mL Schlenk flask, diisopropylamine (5.6 mL, 40.0 mmol) and THF (30 mL) were added and cooled to −78° C. Butyllithium (14.4 mL, 36.0 mmol) (2.5M in hexane) was added dropwise and the mixture was stirred for 30 minutes. The solution of methyl-substituted N-heterocyclic compound (20.0 mmol) in 10 mL THF was added, and the mixture was stirred for 1 h. Di-tert-butyl decarbonate (9.2 mL, 40.0 mmol) was added, and the mixture was stirred at −78° C overnight when temperature was slowly raised to ambient temperature. The reaction was quenched with the aq. NH₄Cl and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude oil was purified by flash column chromatography on silica gel using petroleum ether/ethylacetate (PE: EA = 5:1) as an eluent to afford **S2b**, **S2c**, **S2f** in 63~80% yields.

C. Preparation of ethyl N-heteroaryleacetate S2j

S1j was obtained following the method reported by Alakananda Hajra and co-workers.³ An oven-dried reaction vessel was charged with aniline (913.20 mg, 10.0 mmol), ptolualdehyde (1.22 g, 10.0 mmol), NH₄SCN (1.52g, 2.0 equiv), I_2 (2.58 g, 1.0 equiv) and DMSO (40.0 mL). The reaction mixture was stirred at 110 °C for 12 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was allowed to cool to room temperature and quenched with saturated $Na_2S_2O_3$ solution. Then the reaction mixture was extracted with ethyl acetate and the organic phase was dried over anhydrous Na_2SO_4 . Concentration in vacuo and purification by column chromatography on silica gel using petroleum ether/ethylacetate (PE: EA = 9:1) as an eluent afforded the pure product S1j (2.04 g, 90%).

S1j (1.81 g, 8 mmol) was added to a stirring solution of N-bromosuccinimide (NBS) (1.43 g, 8 mmol) and 2,2'-Azobis(2-methylpropionitrile) (AIBN) (65.68mg, 0.4 mmol) in 40 mL of CCl₄. The solution was refluxed for 4 h. The progress of the reaction was monitored by TLC. The precipitated succinaimide was filtered and the filtrate was concentrated in vacuo to yield a gray oil. **S1** (2.27 g, 94%) was obtained by recrystallization from ethanol.

S2 was obtained following the method reported by Philip DeShong and co-workers.⁴ Trimethyl-silyl cyanide (0.8 mL, 6.0 mmol) and TBAF (6.0 mL, 6.0 mmol) were added to a stirring solution of **S1** (1.22g, 4.00 mmol) in 40 mL of acetonitrile under an atmosphere of nitrogen at 70 °C. The reaction was completed for 12 h. The yellow reaction mixture was concentrated in vacuo, and the resulting crude product was purified by flash chromatography on silica gel (PE: DCM = 9:1) to afford **S2** (0.96 g, 95%) as a white soild.

S2 (1.50 g, 6.0 mmol) was dissolved in anhydrous ethanol (30 mL), HCl (36%, 6 mL) was added. The resulting slurry was refluxed for 12 h. After concentration in vacuo, the resulting residue was dissolved in EtOAc (12 mL) and quenched by aq. NaHCO₃ slowly to achieve pH 8.0 in the aqueous layer. Organic layer was separated and dried over anhydrous Na₂SO₄. Filtration and concentration yielded **S2**_i (1.77 g, 99%).

D. General procedure for preparation of α-N-heteroaryldiazoalkanes 1

p-ABSA, DBU
$$CO_{2}R_{1} \text{ MeCN, 0°C to rt}$$

$$S2a-S2j \text{ overnight}$$

$$R_{1} = \text{Et or }^{t}Bu$$

p-ABSA (10.1 mmol, 1.01 equiv) was added to a solution of **S2** (10 mmol, 1.0 equiv) and DBU (15 mmol, 1.5 equiv) in CH₃CN (50 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight. Then it was concentrated in vacuo and diluted with EtOAc and H₂O. The aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using petroleum ether/ethylacetate as an eluent to afford α -N-heteroaryldiazoalkanes **1a-1j** in 67~99% yields.

Ethyl 2-diazo-2-(pyridin-4-yl) acetate (1a)⁵

1a: Light yellow solid (1.64 g, 86%), mp 55-56 °C; R_f 0.3 (PE: EA = 5:1); ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, J = 6.0 Hz, 2H), 7.40 (d, J = 6.2 Hz, 2H), 4.33 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 149.8, 136.1, 117.2, 82.9, 64.6, 28.3.

Tert-butyl 2-(2-chloropyridin-4-yl)-2-diazoacetate (1c)

1c: Yellow solid (2.34 g, 92%), mp 93-94 °C; R_f 0.3 (PE: EA = 20:1); 1H NMR (400 MHz, CDCl₃) δ 8.20 (d, J = 5.5 Hz, 1H), 7.50 (s, 1H), 7.23 (dd, J = 5.5, 1.8 Hz, 1H), 1.49 (s, 9H). ^{13}C NMR (100 MHz, CDCl₃) δ 162.2, 152.1, 149.4, 139.5, 117.1, 115.6, 83.4, 64.9, 28.3; HRMS-ESI (m/z) calculated for $C_{11}H_{13}ClN_3O_2^+$ [M+H] $^+$ 254.0691, found 254.0692; IR (KBr): 3449, 2983, 2098, 1700, 1590, 1541, 1470, 1149, 1044, 846, 769 cm $^{-1}$.

Ethyl 2-diazo-2-(2,6-dichloropyridin-4-yl) acetate (1d)

1d: Yellow solid (2.31 g, 89%), mp 109-110 °C; R_f 0.55 (PE: EA = 20:1); ¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 2H), 4.34 (q, J= 7.1 Hz, 2H), 1.34 (t, J= 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 151.0, 141.6, 115.4, 64.3, 62.0, 14.4; HRMS-ESI (m/z) calculated for C₉H₈Cl₂N₃O₂ ⁺[M+H]⁺ 259.9988, found 259.9992.

Tert-butyl 2-diazo-2-(2-(p-tolylthio)pyridin-4-yl)acetate (1f)

1f: Orange solid (2.49 g, 73%), mp 45-47 °C; R_f 0.4 (PE: EA = 20:1); ${}^{1}H$ NMR (400 MHz, CDCl₃) δ 8.29 (d, J = 5.5 Hz, 1H), 7.46 (d, J = 7.8 Hz, 2H), 7.21 (d, J = 7.8 Hz, 2H), 7.14 (dd, J = 5.5, 1.8 Hz, 1H), 6.94 (s, 1H), 2.37 (s, 3H), 1.48 (s, 9H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 162.7, 162.0, 149.5, 139.4, 136.9, 135.0, 130.4, 127.2, 114.3, 114.0, 83.0, 64.6, 28.3, 21.3; HRMS-ESI (m/z) calculated for $C_{18}H_{20}N_3O_2S^+$ [M+H] $^+$ 342.1271, found 342.1274; IR (KBr): 3452, 2981, 2923, 2098, 1700, 1575, 1532, 1149, 812 cm $^{-1}$.

Ethyl 2-diazo-2-(2-(piperidin-1-yl)pyridin-4-yl)acetate (1g)

1g: Yellow solid (1.89 g, 69%), mp 49-50 °C; R_f 0.4 (PE: EA = 20:1); ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 5.4 Hz, 1H), 7.03 (d, J = 1.6 Hz, 1H), 6.42 (dd, J = 5.5, 1.6 Hz, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.51 (s, 4H), 1.61 (s, 6H), 1.32 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.2, 160.0, 148.1, 136.2, 106.1, 100.9, 63.9, 61.1, 46.3, 25.6, 24.7, 14.5; HRMS-ESI (m/z) calculated for $C_{14}H_{19}N_4O_2^+$ [M+H]⁺ 275.1503, found 275.1507.

ethyl 2-diazo-2-(quinolin-4-yl) acetate (1h)

1h: Yellow solid (1.89 g, 71%), mp 69-71 °C; R_f 0.4 (PE: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 8.88 (d, J = 4.6 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.77-7.72 (m, 1H), 7.70-7.56 (m, 1H), 7.22 (dd, J = 8.4, 2.4 Hz, 1H), 4.35 (q, J = 7.2 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.96, 149.7, 148.8, 131.9, 130.6, 129.7, 127.0, 126.4, 125.3, 123.8, 121.97, 61.8, 60.5, 14.5; HRMS-ESI (m/z) calculated for C₁₃H₁₂N₃O₂⁺ [M+H]⁺ 242.0924, found 242.0928; IR (KBr): 3439, 3134, 2916, 2098, 1698, 1647, 1577, 1249 cm⁻¹.

ethyl 2-diazo-2-(pyridin-3-yl)acetate (1i) 6

1i

1i: Yellow solid (1.89 g, 99%), mp 39-40 °C; R_f 0.3 (PE : EA = 5:1); IR (KBr): 3422, 3127, 2983, 2091, 1702, 1560, 1484, 1420, 1399, 1385, 1342, 1257, 1192, 1172, 1061, 1033, 802, 739, 706, 619 cm⁻¹.

Ethyl 2-(4-(benzo[d]thiazol-2-yl)phenyl)-2-diazoacetate (1j)

1j: Yellow solid (2.71 g, 84%), mp 126-127 °C; R_f 0.4 (PE : EA = 5:1); ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, J = 8.6 Hz, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 8.6 Hz, 2H), 7.51-7.47 (m, 1H), 7.40-7.36 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.4, 164.6, 154.1, 134.9, 130.7, 128.8, 128.0, 126.4, 125.2, 123.7, 123.1, 121.6, 64.2, 61.3, 14.5; HRMS-ESI (m/z) calculated for C₁₇H₁₃N₃O₂SNa⁺ [M+Na]⁺ 346.0621, found 346.0626; IR (KBr): 3422, 3134, 2961, 2923, 2852, 2088, 1706, 1647, 1654, 1636, 1559, 1541, 1522, 1507, 1458, 1399, 1385, 1270, 1163, 1084, 1028, 756, 726,619 cm⁻¹.

III. N-alkylation of substrates 1

Methods for N-alkylation taking 1a for example

$$N_2$$
 CO_2Et
 N_2
 $R-X$
 CO_2Et
 CO_2Et
 CO_2Et
 CO_2Et
 CO_2Et

Method a: To a 10 mL pressure tube, methyl iodide CH₃I (0.2 mL, 3 mmol) was added to a solution of α-4-pyridyldiazoester 1a (191.2 mg, 1 mmol) in CH₂Cl₂ (1 mL). The tube was sealed and the reaction mixture was stirred at room temperature for 6 h. The crude product was purified by recrystallization with acetone and diethyl ether. 2a-I (319.8 mg, 96%) was obtained as a khaki solid.

Method b: Follow the method reported by Radek Cibulka and co-workers.⁷ Methyl triflate MeOTf (0.12 mL, 1.0 mmol) was added dropwise to the solution of α-4-pyridyldiazoester **1a** (191.2 mg, 1 mmol, 1 equiv) in dry CH₂Cl₂ (1 mL) at 0 °C under argon. The progress of the reaction was monitored by TLC. Solid was precipitated and collected by filtration. Or the reaction mixture was concentrated and the crude product was purified by recrystallization with acetone and diethyl ether. **2a-OTf** (305.5 mg, 86% yield) was obtained as a yellow semicrystalline solid.

Method c: In glovebox, Et₃O⁺BF₄⁻ (1.0 mmol, 147.9 mg) was added to a solution of α-4-pyridyldiazoester **1a** (191.2 mg, 1 mmol, 1 equiv) in CH₂Cl₂ (1 mL). The reaction was stirred at rt for 1 h. The reaction mixture was concentrated and the crude product was purified by recrystallization with acetone and diethyl ether. **2a-BF**₄ (278.4 mg, 95%) was obtained as a khaki solid.

Method d: Benzyl bromide (1.1 mmol, 1.1 equiv) was added to a solution of α-4-pyridyldiazoester 1a (1 mmol, 1.0 equiv.) in MeCN (5 mL). The mixture was heated with stirring for 8 h in an oil bath (80°C). Solid was precipitated and purified by recrystallization with acetone and diethyl ether. 2a'-Br (318.8 mg, 88%) was obtained as a khaki solid.

4-(1-diazo-2-ethoxy-2-oxoethyl)-1-methylpyridin-1-ium (2a-BF4)

2a-BF₄: Yellow solid (278.4 mg, 95%), mp 86-88 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.96 (d, J = 7.3 Hz, 2H), 8.23 – 8.06 (m, 2H), 4.50 (s, 3H), 4.38 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 160.9, 146.1, 144.0, 118.8, 77.0, 68.1, 62.4, 47.8, 14.1. HRMS-ESI (m/z) calculated for C₁₀H₁₂N₃O₂⁺ [M-BF₄⁻]⁺ 206.0924, found 206.0933; IR (KBr): 3432, 3134, 2961, 2922, 2120, 1701, 1685, 1653,

1636, 1559, 1458, 1340, 1384, 1244, 1084, 1039, 619 cm⁻¹.

1-benzyl-4-(1-diazo-2-ethoxy-2-oxoethyl) pyridin-1-ium bromide (2a'-Br)

2a'-Br

2a'-Br: Khaki solid (318.8 mg, 88%), mp: 121-123 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.22 (d, J = 7.1 Hz, 2H), 8.06 (d, J = 7.2 Hz, 2H), 7.70 – 7.49 (m, 2H), 7.36 – 7.27 (m, 3H), 6.03 (s, 2H), 4.32 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 161.1, 146.5, 143.6, 133.4, 129.7, 129.5, 129.5, 119.1, 68.3, 62.6, 62.6, 14.3; IR (KBr): 3422, 3133, 2963, 2921, 2120, 1773, 1735, 1701, 1685, 1654, 1647, 1636, 1570, 1534, 1458, 1400, 1384, 1244, 1083, 1040, 620 cm⁻¹.

4-(2-(tert-butoxy)-1-diazo-2-oxoethyl)-1-methylpyridin-1-ium tetrafluoroborate (2b-BF₄)

2b-BF₄

2b-BF4: Khaki solid (295.4 mg, 92%), mp 110-112 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.38 (d, J = 6.8 Hz, 2H), 7.92 (d, J = 6.6 Hz, 2H), 4.16 (s, 3H), 1.48 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 146.9, 143.8, 118.9, 84.8, 68.6, 47.0, 28.2; HRMS-ESI (m/z) calculated for C₁₂H₁₆N₃O₂⁺ [M-BF₄⁻] + 234.1237, found 234.1241.

4-(2-(tert-butoxy)-1-diazo-2-oxoethyl)-2-chloro-1-methylpyridin-1-ium tetrafluoroborate (2c-BF4)

$†$
BuO₂C N_2
 CI
 N_2
 BF_4
 Me
 $\mathbf{2c-BF_4}$

RF4 · Lio

2c-BF₄: Light yellow solid (298.6 mg, 84%), mp 133-134 °C; ¹H NMR (400 MHz, d₆-DMSO) δ 8.77 (d, J = 7.0 Hz, 1H), 8.19 (s, 1H), 8.03 (dd, J = 7.0, 2.4 Hz, 1H), 4.12 (s, 3H), 1.49 (s, 9H); ¹³C NMR (100 MHz, d₆-DMSO) δ 159.8, 148.8, 147.0, 145.6, 119.8, 117.3, 85.5, 69.2, 47.1, 28.2; HRMS-ESI (m/z) calculated for $C_{12}H_{15}CIN_3O_2^+$ [M-BF₄⁻]⁺ 268.0847, found 268.0851; IR (KBr): 3423, 3134, 2961, 2921, 2851, 1697, 1654, 1637, 1560, 1542, 1523, 1458, 1399, 1384, 1270, 1215, 1157, 1083, 1069, 788, 762,

679, 620, 562 cm⁻¹.

$2,6-dichloro-4-(1-diazo-2-ethoxy-2-oxoethyl)-1-methyl pyridin-1-ium \\tetrafluoroborate$

2d-BF₄: Light yellow solid (298.6 mg, 84%), mp 140-141 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 2H), 4.36 (q, J = 7.5 Hz, 2H), 4.29 (s, 3H), 1.35(t, J = 6.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.80, 148.65, 147.32, 118.50, 69.12, 62.89, 43.24, 14.26; HRMS-ESI (m/z) calculated for C₁₀H₁₀Cl₂N₃O₂⁺ [M-BF₄⁻]⁺ 274.0145, found 274.0147.

$\hbox{$2$-cyano-4-(1-diazo-2-ethoxy-2-oxoethyl)-1-methylpyridin-1-ium tetrafluoroborate ($2e$-BF$_4)} \\$

2e-BF₄: Light yellow solid (279.9 mg, 84%), mp 131-133 °C; ¹H NMR (400 MHz, d₆-DMSO) δ 8.94 (d, J = 7.0 Hz, 1H), 8.70 (d, J = 2.5 Hz, 1H), 8.36 (dd, J = 6.9, 2.5 Hz, 1H), 4.35 (q, J = 7.2 Hz, 2H), 4.32 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 161.2, 146.9, 146.7, 126.2, 124.3, 120.1, 111.2, 70.3, 62.3, 46.4, 14.0; IR (KBr): 3435, 2955, 2926, 2109, 1700, 1626, 1558, 1260, 1042, 519 cm⁻¹.

4-(2-(tert-butoxy)-1-diazo-2-oxoethyl)-1-methyl-2-(p-tolylthio)

pyridin-1-ium tetrafluoroborate (2f-BF4)

2f-BF₄

2f-BF₄: Light yellow solid (385.6 mg, 87%), decomposed at 142 °C; ¹H NMR (400 MHz, d₆-DMSO) δ 8.70 (d, J = 7.0 Hz, 1H), 7.69 – 7.53 (m, 3H), 7.47 (d, J = 7.9 Hz, 2H), 7.37 (s, 1H), 4.15 (s, 3H), 2.41 (s, 3H), 1.38 (s, 9H); ¹³C NMR (100 MHz, d₆-

DMSO) δ 160.6, 158.2, 145.2, 144.5, 142.1, 135.5, 131.7, 121.6, 115.7, 114.8, 83.8, 68.7, 44.5, 27.5, 20.9; HRMS-ESI (m/z) calculated for C₁₉H₂₂N₃O₂S⁺[M-BF₄⁻]⁺ 356.1427, found 356.1428; IR (KBr): 3438, 2986, 2129, 1703, 1620, 1532, 1504, 1453, 1147, 1041 cm⁻¹.

4-(1-diazo-2-ethoxy-2-oxoethyl)-1-methyl-2-(piperidin-1-yl)pyridin-1-ium tetrafluoroborate (2g-BF₄)

$$\begin{array}{c|c} \mathsf{EtO_2C} & \mathsf{N_2} \\ \\ \bar{\mathsf{BF_4}} & \mathsf{N} & \mathsf{N} \\ \\ \mathsf{Me} & \\ \end{array}$$

2g-BF₄

2g-BF₄: Khaki solid (293.4 mg, 78%), mp 171-172 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, J = 5.4 Hz, 1H), 7.89 (s, 1H), 7.75 (dd, J = 5.4, 1.4 Hz, 1H), 4.57 (d, J = 13.1 Hz, 2H), 4.34 (q, J = 7.1 Hz, 2H), 3.82 (td, J = 12.4, 2.9 Hz, 2H), 3.42 (s, 3H), 2.00 – 1.90 (m, 2H), 1.77 – 1.56 (m, 4H), 1.34 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.1, 154.4, 149.2, 142.5, 118.8, 108.8, 65.5, 61.9, 61.5, 57.4, 21.4, 20.7, 14.4; HRMS-ESI (m/z) calculated for C₁₅H₂₁N₄O₂ [M-BF₄⁻]⁺ 289.1659, found 289.1659.

4-(1-diazo-2-ethoxy-2-oxoethyl)-1-methylquinolin-1-ium tetrafluoroborate (2h-BF₄)

2h-BF₄

2h-BF4: Light yellow solid (305.4 mg, 89%), mp 151-153 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.79 (d, J = 6.5 Hz, 1H), 8.46 (d, J = 8.9 Hz, 1H), 8.20 (d, J = 6.2 Hz, 1H), 8.17 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 8.6 Hz, 1H), 7.93 (t, J = 7.8 Hz, 1H), 4.73 (s, 3H), 4.33 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 147.8, 144.9, 138.8, 136.2, 130.0, 126.1, 124.6, 120.2, 119.6, 65.5, 62.9, 46.6, 14.4; IR (KBr): 3441, 2918,2109, 1714, 1609, 1368, 1255, 1167, 1101, 1016, 772 cm⁻¹.

3-(1-diazo-2-ethoxy-2-oxoethyl)-1-methylpyridin-1-ium tetrafluoroborate (2i-BF4)

$$N_2$$
 CO_2Et N_2 CO_2Et N_2 CO_3Et N_4 N_4 N_4 N_6

2i-BF₄

2i-BF₄: Orange solid (240.3 mg, 82%), mp 62.4-63.4 °C; ¹H NMR (400 MHz, d₆-

DMSO) δ 9.11 (s, 1H), 8.72 (d, J = 6.0 Hz, 1H), 8.57 (d, J = 8.5 Hz, 1H), 8.09 (t, J = 7.3 Hz, 1H), 4.36 (s, 3H), 4.34-4.31 (m, 2H), 1.30 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 163.1, 141.4, 139.2, 137.8, 128.8, 127.1, 62.7, 61.7, 48.3 14.1; HRMS-ESI (m/z) calculated for C₁₀H₁₂N₃O₂⁺[M-BF₄⁻]⁺ 206.0924, found 206.0927; IR (KBr): 3448, 3147, 2923, 2095, 1685, 1654, 1648, 1508, 1458, 1399, 1384, 1260, 1163, 1084, 1057, 1037, 816, 674 cm.

$2\hbox{-}(4\hbox{-}(1\hbox{-}diazo\hbox{-}2\hbox{-}ethoxy\hbox{-}2\hbox{-}oxoethyl) phenyl)\hbox{-}3\hbox{-}methylbenzo[d] thiazol\hbox{-}3\hbox{-}ium tetrafluoroborate (2j-BF4) }$

$$N_2$$
 Me
 N
 BF_4
 S

2j-BF₄: Light yellow solid (391.3 mg, 92%), decomposed at 109 °C; ¹H NMR (400 MHz, d₆-DMSO) δ 8.51 (d, J = 8.3 Hz, 1H), 8.39 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.3 Hz, 3H), 7.89 (d, J = 8.1 Hz, 3H), 4.32 (q, J = 7.1 Hz, 2H), 4.26 (s, 3H), 1.30 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 173.6, 163.6, 142.5, 132.7, 131.0, 129.8, 128.6, 124.4, 123.8, 123.7, 121.6, 117.6, 64.8, 61.3, 38.0, 14.2; HRMS-ESI (m/z) calculated for C₁₈H₁₆N₃O₂S⁺[M-BF₄⁻]⁺ 338.0958, found 338.0958; IR (KBr): 3422, 3134, 2961, 2921, 2851, 2096, 1869, 1845, 1773, 1735, 1685, 1654, 1647, 1636, 1636, 1559, 1540, 1522, 1507, 1400, 1385, 1270, 1084, 1037, 669, 619 cm⁻¹.

IV. Transformations of α -N-heteroaryldiazoalkane tetrafluoroborates enabled by Rhodium catalysis

General Procedure for cyclopropenation of 2-BF4

A solution of α -N-heteroaryldiazoalkane tetrafluoroborates **2-BF**₄ (0.3 mmol, 1 equiv) in DCM (0.3 M) was added dropwise to a stirred solution of alkene (0.9 mmol, 3 equiv) in DCM at room temperature. The progress of the reaction was monitored by TLC. After completion (0.5-12 h), the reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography.

One-pot procedure

In the glovebox, Et₃O⁺BF₄⁻ (0.33 mmol, 47 mg, 1.1 equiv) was added to a solution of α-N-heteroaryldiazoalkanes 1 (0.30 mmol, 1 equiv) in CH₂Cl₂ (1 mL) containing 4 Å molecular sieves (0.1 g) at room temperature. The progress of the reaction was monitored by TLC. After completion (1 h to 24 h), 3 equiv of terminal alkenes 3a-c, terminal alkynes 4a-c, allyl thioethers 7, or propargyl thioether 8 was added, followed by the addition of Rh₂(OAc)₄ (3.4 mg, 2 mol%). The resulting reaction solution was stirred at room temperature for 2-12 h, monitored by TLC. Then the reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography (30:1 DCM/MeOH) to give the products 5, 6, 9.

4-(1-(ethoxycarbonyl)-2-(naphthalen-2-yl)cycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (5a)

5a: Followed **One-pot procedure**. White solid (94.5 mg, 86%), mp 67-69 °C; R_f 0.1 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, J = 6.2 Hz, 2H), 7.64 (d, J = 6.1 Hz, 2H), 7.27 – 6.68 (m, 5H), 4.22 (s, 3H), 4.16-4.12 (m, 2H), 3.33 (s, 1H), 2.24 (d, J = 8.5 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.93, 155.56, 144.09, 133.30, 130.89, 128.79, 128.12, 127.74, 62.53, 47.97, 36.78, 35.21, 18.82, 14.00; HRMS-ESI (m/z) calculated for C₁₈H₂₀NO₂⁺ [M-BF₄⁻]⁺ 282.1489, found 282.1489.

4-(1-(ethoxycarbonyl)-2-methyl-2-phenylcyclopropyl)-1-methylpyridin-1-ium tetrafluoroborate (5b)

5b : Followed **One-pot procedure**. White solid (98.9 mg, 86%), mp 75-76 °C; R_f 0.1 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, J = 6.3 Hz, 2H), 7.75 (d, J = 6.5 Hz, 2H), 7.20 – 6.94 (m, 5H), 4.28 – 4.19 (m, 2H), 4.17 (s, 3H), 2.41 (d, J = 6.6 Hz, 1H), 2.26 (d, J = 6.5 Hz, 1H), 1.71 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.10, 157.16, 143.54, 138.67, 129.61, 128.92, 127.95, 127.68, 62.53, 47.71, 40.97, 40.05, 23.30, 22.51, 14.17; HRMS-ESI (m/z) calculated for C₁₉H₂₂NO₂⁺ [M-BF₄⁻]⁺ 296.1645, found.296.1653.

4-(1-(tert-butoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methylpyridin-1-ium tetrafluoroborate (5c)

5c: Followed **General procedure for cyclopropenation of 2-BF**4. White solid (100.8 mg, 71%), mp 81-82 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 8.72 (d, J = 6.5 Hz, 2H), 8.27 (d, J = 6.7 Hz, 2H), 7.70 – 7.62 (m, 2H), 7.36 – 7.25 (m, 4H), 7.21 (t, J = 7.1 Hz, 1H), 7.03 (t, J = 7.5 Hz, 2H), 6.99 – 6.93 (m, 2H), 4.15 (s, 3H), 2.86 (d, J = 6.4 Hz, 1H), 2.61 (d, J = 6.3 Hz, 1H), 1.04 (s, 9H); ¹³C NMR (100 MHz, d₆-DMSO) δ 176.1, 166.4, 155.1, 143.9, 141.3, 139.1, 130.0, 129.5, 129.1, 128.33, 128.28, 127.1, 82.0, 47.9, 47.1, 41.6, 26.9, 22.0; HRMS-ESI (m/z) calculated for C₂₆H₂₈NO₂⁺ [M-BF₄⁻]⁺ 386.2115, found 386.2115.

4-(1-(tert-butoxycarbonyl)-2,2-diphenylcyclopropyl)-2-chloro-1-methylpyridin-1-ium (5d)

5d : Followed **General procedure for cyclopropenation of 2-BF**₄. Light yellow solid (117.3 mg, 77%), mp 100-102 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, J = 6.5 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.89 (dd, J = 6.5, 2.1 Hz, 1H), 7.52 (d, J = 7.1 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.26-7.24 (m, 1H), 7.18-7.12 (m, 4H), 7.04 (t, J = 7.1 Hz, 1H), 4.27 (s, 3H), 2.91 (d, J = 6.5 Hz, 1H), 2.71 (d, J = 6.6 Hz, 1H), 1.13 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 159.4, 147.2, 145.0, 140.0, 137.8, 130.9, 129.4, 129.0, 128.8, 128.7, 127.9, 127.73, 127.70, 83.7, 49.6, 47.1, 42.3, 27.3, 23.3; HRMS-ESI (m/z) calculated for C₂₆H₂₇ClNO₂⁺ [M-BF₄⁻]⁺ 420.1725, found 420.1726.

2,6-dichloro-4-(1-(ethoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methylpyridin-1-ium tetrafluoroborate (5e)

5e: Followed **One-pot procedure**. Yellow solid (121.8 mg, 79%), mp 82-83 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 14.3 Hz, 1H), 7.58 – 7.28 (m, 11H), 4.74 (q, J = 7.1 Hz, 2H), 4.14 (s, 3H), 3.81 (s, 2H), 1.56 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.4, 150.7, 142.3, 128.9, 128.63, 125.6, 117.9, 94.97, 84.3, 77.3, 69.6, 41.8, 15.1; HRMS-ESI (m/z) calculated for C₂₄H₂₂Cl₂NO₂⁺ [M-BF₄⁻]⁺ 426.1022, found 426.1026.

4-(1-(tert-butoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methyl-2-(p-tolylthio)pyridin-1-ium tetrafluoroborate (5f)

t
BuO₂C Ph
Ph
 $^{+}$ $^{-}$ $^{-}$ BF₄
Me STol

5f: Followed **General procedure for cyclopropenation of 2-BF**4. Light yellow solid (126.2 mg, 89%), mp 139-140 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 8.76 (d, J = 6.6 Hz, 1H), 7.83 (dd, J = 6.6, 2.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.36 – 7.30 (m, 2H), 7.30 – 7.24 (m, 2H), 7.24 – 7.20 (m, 1H), 7.17-7.13 (m, 2H), 7.08 (d, J = 7.3 Hz, 1H), 7.02 – 6.95 (m, 3H), 4.11 (s, 3H), 2.54 – 2.48 (m, 2H), 2.50 (s, 3H), 0.99 (s, 9H); ¹³C NMR (100 MHz, d₆-DMSO) δ 165.8, 157.9, 153.3, 145.7, 142.5, 140.6, 138.5, 135.7, 131.8, 129.3, 128.8, 128.4, 128.3, 127.7, 127.2(4), 127.2(0), 124.8, 121.5, 82.1, 47.4, 45.3, 41.8, 26.9, 22.1, 21.0; HRMS-ESI (m/z) calculated for C₃₃H₃₄NO₂S⁺ [M-BF₄⁻]⁺ 508.2305, found 508.2309.

4-(1-(ethoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methyl-2-(piperidin-1-yl)pyridin-1-ium tetrafluoroborate (5g)

5g: Followed **General procedure for cyclopropenation of 2-BF**4. Light yellow solid (118.8 mg, 75%), mp 108-110 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d6-DMSO) δ 8.44 (d, J = 5.0 Hz, 1H), 8.10 (d, J = 2.8 Hz, 1H), 7.75 (d, J = 5.1 Hz,

1H), 7.68 (d, J = 7.5 Hz, 2H), 7.38 – 7.31 (m, 4H), 7.27 (t, J = 7.3 Hz, 1H), 7.05 (t, J = 7.6 Hz, 2H), 6.96 (t, J = 7.3 Hz, 1H), 4.51 (d, J = 13.2 Hz, 1H), 4.44 (d, J = 12.7 Hz, 1H), 3.87 – 3.80 (m, 1H), 3.73 – 3.68 (m, 2H), 3.68-3.65 (m, 1H), 3.24 (s, 3H), 2.98 (d, J = 6.4 Hz, 1H), 2.61 (d, J = 6.3 Hz, 1H), 1.92 – 1.71 (m, 2H), 1.55-1.48 (m, 2H), 1.40 – 1.24 (m, 1H), 1.18 – 1.03 (m, 1H), 0.82 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d6-DMSO) δ 168.4, 153.2, 150.5, 148.1, 141.6, 139.1, 129.4, 129.1, 128.2, 127.96, 127.0, 126.7, 119.9, 61.1, 61.1, 60.7, 46.9, 40.8, 21.5, 20.7, 20.5, 13.3; HRMS-ESI (m/z) calculated for C₂₉H₃₃N₂O₂+ [M-BF₄-]+ 441.2537, found 441.2538.

4-(1-(ethoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methylquinolin-1-ium tetrafluoroborate (5h)

$$EtO_2C$$
 Ph

$$-BF_4$$
 N N Me

5h: Followed **General procedure for cyclopropenation of 2-BF4**. White solid (111.4 mg, 75%), mp 109-110 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 9.13 (s, 1H), 8.60 (d, J = 8.5 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 8.12 (t, J = 7.5 Hz, 1H), 7.96 – 7.71 (m, 2H), 7.56 (d, J = 7.5 Hz, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1H), 7.03 – 6.77 (m, 5H), 4.62 (s, 3H), 3.96-3.91 (m, 1H), 3.82 – 3.63 (m, 1H), 3.11 (d, J = 5.9 Hz, 1H), 2.79 (s, 1H), 0.86 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 140.0, 138.7, 138.6, 137.2, 135.1, 130.2, 130.1, 128.8, 128.4, 127.97, 127.9, 127.5, 126.9, 62.5, 45.9, 41.4, 29.7, 25.7, 13.5; HRMS-ESI (m/z) calculated for C₂₈H₂₆NO₂⁺ [M-BF₄⁻]⁺ 408.1958, found 408.1957.

2-(4-(1-(ethoxycarbonyl)-2,2-diphenylcyclopropyl)phenyl)-3-methylbenzo[d]thiazol-3-ium tetrafluoroborate (5i)


5i: Followed **General procedure for cyclopropenation of 2-BF**₄. White solid (83.6 mg, 48%), mp 136-137 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 8.49 (d, J = 8.2 Hz, 1H), 8.36 (d, J = 8.5 Hz, 1H), 7.98 (t, J = 7.9 Hz, 1H), 7.87 (d, J = 8.5 Hz, 3H), 7.74 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 7.6 Hz, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.28 (d, J = 7.6 Hz, 3H), 7.06 (t, J = 7.5 Hz, 2H), 6.98 (d, J = 7.3 Hz, 1H), 4.09 (s, 3H), 3.86-3.78 (m, 1H), 3.69-3.61 (m, 1H), 2.80 (d, J = 6.1 Hz, 1H), 2.65 (d, J = 6.0 Hz, 1H), 0.79 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 173.8, 169.3, 142.3,

142.0, 139.5, 133.1, 129.9, 129.5, 129.2, 129.1, 128.6, 128.3, 127.8, 126.9, 126.4, 124.4, 123.6, 117.6, 60.9, 45.7, 41.7, 37.8, 21.8, 13.3; HRMS-ESI (m/z) calculated for $C_{32}H_{28}NO_2S^+$ [M-BF₄-]⁺ 490.1835, found 490.1834.

3-(1-(ethoxycarbonyl)-2,2-diphenylcyclopropyl)-1-methylpyridin-1-ium tetrafluoroborate (5j)

5j : Followed **One-pot procedure**. White solid (119.2 mg, 89%), mp 70-72 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 9.25 (s, 1H), 8.74-8.69 (m, 2H), 7.93-7.90 (m, 1H), 7.68 (d, J = 7.5 Hz, 2H), 7.38-7.34 (m, 4H), 7.27 (t, J = 7.4 Hz, 1H), 7.09 (t, J = 7.6 Hz, 2H), 7.00 (t, J = 7.3 Hz, 1H), 4.27 (s, 3H), 3.84-3.80 (m, 1H), 3.67-3.63 (m, 1H), 2.94 (d, J = 6.4 Hz, 1H), 2.67 (d, J = 6.4 Hz, 1H), 0.75 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 168.4, 148.0, 147.8, 143.8, 141.4, 138.8, 136.7, 129.4, 129.0, 128.3, 127.1, 127.0, 126.1, 61.3, 47.6, 46.4, 38.7, 21.4, 13.2; HRMS-ESI (m/z) calculated for C₂₄H₂₄NO₂⁺ [M-BF₄⁻]⁺ 358.1802, found 358.1803.

3-(1-(ethoxycarbonyl)-2-methyl-2-phenylcyclopropyl)-1-methylpyridin-1-ium (5k)



5k: Followed **One-pot procedure**. White solid (94.3 mg, 82%), mp 76-78 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 8.89 (s, 1H), 8.61 (d, J = 6.0 Hz, 1H), 8.34 (d, J = 8.2 Hz, 1H), 7.78 (t, J = 7.1 Hz, 1H), 7.22-7.04 (m, 5H), 4.19 (s, 3H), 4.17-4.11 (m, 2H), 2.65 (d, J = 6.5 Hz, 1H), 2.06 (d, J = 6.3 Hz, 1H), 1.72 (s, 3H), 1.20 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 168.8, 147.9, 146.9, 143.6, 139.6, 137.5, 128.3, 127.9, 127.0, 125.9, 61.7, 47.5, 37.9, 36.6, 21.8, 21.0, 13.9; HRMS-ESI (m/z) calculated for C₁₉H₂₂NO₂⁺ [M-BF₄⁻]⁺ 296.1645, found 296.1644.

3-(1-(ethoxycarbonyl)-2-phenylcyclopropyl)-1-methylpyridin-1-ium tetrafluoroborate (5l)

5l: Followed **One-pot procedure**. White solid (105.2 mg, 95%), mp 72-73 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 8.58 (d, J = 6.0 Hz,

1H), 7.92 (d, J = 8.1 Hz, 1H), 7.67 (t, J = 6.8 Hz, 1H), 7.20 – 7.02 (m, 3H), 6.95 (d, J = 7.6 Hz, 2H), 4.31 (s, 3H), 4.19-4.11 (m, 2H), 3.28 (t, J = 8.4 Hz, 1H), 2.39 (t, J = 6.9 Hz, 1H), 2.28-2.24 (m, 1H), 1.19 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 148.4, 147.2, 143.7, 137.7, 133.8, 128.7, 128.3, 127.5, 126.9, 62.3, 48.3, 34.3, 33.6, 18.4, 13.96; HRMS-ESI (m/z) calculated for C₁₈H₂₀NO₂⁺ [M-BF₄⁻]⁺ 282.1489, found 282.1489.

4-(1-(ethoxycarbonyl)-2-phenylcycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (6a)

Ph
$$CO_2Et$$
 N^+ BF_4 Me

6a: Followed **One-pot procedure**. White solid (83.7 mg, 76%), mp 86-88 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 6.4 Hz, 2H), 8.05 (d, J = 6.5 Hz, 2H), 7.58 – 7.32 (m, 5H), 7.18 (s, 1H), 4.29 (s, 3H), 4.21-4.16 (m, 2H), 1.20 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 161.4, 144.1, 131.3, 130.3, 129.4, 127.0, 122.8, 113.2, 96.6, 61.8, 47.6, 33.1, 14.1; HRMS-ESI (m/z) calculated for C₁₈H₁₈NO₂⁺ [M-BF₄⁻]⁺ 280.1332, found 280.1339.

4-(1-(ethoxycarbonyl)-2-(naphthalen-2-yl)cycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (6b)

$$CO_2Et$$
 BF_4

6b : Followed **One-pot procedure**. Yellow solid (41.9 mg, 32%), mp 134-136 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 8.74 (d, J = 6.5 Hz, 2H), 8.15 (s, 1H), 8.07 (d, J = 6.5 Hz, 2H), 8.01 (d, J = 8.6 Hz, 1H), 7.97-7.92 (m, 2H), 7.87 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.55 (p, J = 7.1 Hz, 2H), 4.83 (q, J = 7.0 Hz, 2H), 4.20 (s, 3H), 1.57 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 160.99, 147.5, 145.3, 144.96, 133.5, 132.6, 129.2, 128.4, 128.2, 127.5, 126.8, 126.7, 126.2, 121.6, 121.1, 121.1, 106.1, 96.9, 69.5, 55.4, 46.9, 15.3; HRMS-ESI (m/z) calculated for C₂₂H₂₀NO₂⁺ [M-BF₄⁻]⁺ 330.1489, found 330.1489.

3-(1-(ethoxycarbonyl)-2-phenylcycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (6c)

6c : Followed **One-pot procedure**. White solid (94.2 mg, 85%), mp 74-76 °C; R_f 0.2 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 8.51 (d, J = 5.9 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 7.77 (t, J = 7.2 Hz, 1H), 7.48 (d, J = 7.2 Hz, 2H), 7.40 – 7.24 (m, 4H), 4.26 (s, 3H), 4.07 (d, J = 7.1 Hz, 2H), 1.09 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 145.2, 144.40 143.1, 142.9, 131.1, 130.1, 129.3, 127.4, 123.3, 115.2, 97.1, 61.9, 48.6, 30.8, 14.1; HRMS-ESI (m/z) calculated for C₁₈H₁₈NO₂⁺ [M-BF₄⁻]⁺ 280.1332, found 280.1332.

3-(2-((benzyloxy)methyl)-1-(ethoxycarbonyl)cycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (6d)

6d : Followed **One-pot procedure**. White solid (55.5 mg, 45%), mp 81-83 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.74 (s, 1H), 8.57 (d, J= 6.1 Hz, 1H), 8.38-8.35 (m, 1H), 7.82 (dd, J= 8.1, 6.1 Hz, 1H), 7.35 - 7.24 (m, 5H), 7.13 (s, 1H), 4.69-4.57 (m, 2H), 4.56-4.52 (m, 2H), 4.27 (s, 3H), 4.17-4.11 (m, 2H), 1.20 (t, J= 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.3, 145.6, 145.2, 143.0, 142.8, 137.2, 128.6, 128.2, 128.0, 127.3, 115.0, 99.3, 73.1, 62.4, 61.9, 48.5, 31.1, 14.2; HRMS-ESI (m/z) calculated for C₂₀H₂₂NO₃⁺ [M-BF₄⁻]⁺ 324.1594, found 324.1593.

4-(1-(ethoxycarbonyl)-2-(naphthalen-2-yl)cycloprop-2-en-1-yl)-1-methylpyridin-1-ium tetrafluoroborate (6e)

6e : Followed **One-pot procedure**. White solid (67.2 mg, 76%), mp 101-103 °C; R_f 0.3 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, d₆-DMSO) δ 9.16 (s, 1H), 8.79-8.71 (m, 2H), 8.17-8.13 (m, 2H), 8.08 – 7.89 (m, 3H), 7.81 (d, J = 8.6 Hz, 1H), 7.75 (s, 1H), 7.63 – 7.43 (m, 2H), 4.73 (q, J = 7.1 Hz, 2H), 4.40 (s, 3H), 1.54 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 172.0, 145.3, 144.6, 143.6, 141.3, 133.6, 132.7, 130.0, 129.1, 128.5, 128.0, 127.8, 127.1, 127.0, 126.2, 121.0, 116.1, 98.5, 61.2, 48.0, 30.6,

14.0; HRMS-ESI (m/z) calculated for $C_{22}H_{20}NO_2^+$ [M-BF₄⁻]⁺ 330.1489, found 330.1489.

4-(1-ethoxy-1-oxo-2-(p-tolylthio)pent-4-en-2-yl)-1-methylpyridin-1-ium tetrafluoroborate (9a)

9a: Followed **One-pot procedure**. Reddish brown solid (60.2 mg, 64%), mp 98-100 °C; R_f 0.4 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, J = 6.5 Hz, 2H), 7.83 (d, J = 6.5 Hz, 2H), 7.06 (s, 4H), 5.73-5.65 (m, 1H), 5.14-5.05 (m, 2H), 4.42 (s, 3H), 4.27 – 4.10 (m, 2H), 3.00-2.95 (m, 1H), 2.86-2.80 (m, 1H), 2.29 (s, 3H), 1.21 (t, J = 7.1 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 168.7, 159.0, 144.6, 141.3, 136.8, 130.4, 130.3, 127.4, 124.7, 121.3, 63.0, 62.9, 48.2, 40.7, 21.3, 13.9; HRMS-ESI (m/z) calculated for C₂₀H₂₄NO₂S [M-BF₄⁻]⁺ 342.1522, found 342.1523.

4-(1-ethoxy-1-oxo-3-phenyl-2-(p-tolylthio)pent-4-en-2-yl)-1-methylpyridin-1-ium tetrafluoroborate (9b)

9b: Followed **One-pot procedure**. Reddish brown solid (62.1 mg, 70%), mp 110-112 °C; R_f 0.45 (DCM/MeOH= 30/1). **9b** was an inseparable mixture of two isomers. The area of pyridine-H peak in major isomer was compared with that in minor isomer to derive a ¹H NMR ratio of dr = 10: 3. The major isomer : ¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, J = 6.5 Hz, 2H), 7.84 (d, J = 6.5 Hz, 2H), 7.25 – 7.16 (m, 3H), 7.09 (d, J = 8.2 Hz, 2H), 7.06 – 6.95 (m, 2H), 6.89 – 6.83 (m, 2H), 6.02 – 5.75 (m, 1H), 5.46 – 5.37 (m, 1H), 5.33 (dd, J = 10.0, 1.5 Hz, 1H), 4.74 (d, J = 10.2 Hz, 1H), 4.45 (s, 3H), 4.06 – 3.99 (m, 1H), 3.91 – 3.83 (m, 1H), 2.22 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.8, 156.1, 143.2, 140.7, 137.5, 135.6, 132.5, 130.5, 130.1, 129.5, 128.6, 126.2, 121.6, 69.2, 62.6, 56.5, 48.2, 21.2, 13.7; The minor isomer : ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, J = 6.5 Hz, 2H), 8.04 (d, J = 6.6 Hz, 2H), 7.25 – 7.22 (m, 3H), 7.09 (d, J = 8.1 Hz, 2H), 7.05 – 6.96 (m, 2H), 6.89 – 6.83 (m, 2H), 6.01 – 5.90 (m, 1H), 5.29 – 5.22 (m, 1H), 4.67 (d, J = 9.5 Hz, 1H), 4.13 – 4.06 (m, 1H), 3.97 – 3.91 (m, 1H), 2.20 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 156.1, 143.4, 140.7, 137.52, 135.5, 134.7, 132.5, 130.8, 129.5, 128.4, 126.1, 121.6, 69.6, 62.6,

57.3, 48.2, 21.2, 13.7; HRMS-ESI (m/z) calculated for $C_{26}H_{28}NO_2S^+$ [M-BF₄⁻]⁺ 418.1835, found 418.1841.

4-(2-(benzylthio)-1-ethoxy-1-oxopent-4-en-2-yl)-1-methylpyridin-1-ium tetrafluoroborate (9c)

BnS
$$CO_2$$
Et

9c: Followed **One-pot procedure**. Reddish brown solid (90.2 mg, 70%), mp 100-102 °C; R_f 0.45 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J = 6.5 Hz, 2H), 7.96 (d, J = 6.4 Hz, 2H), 7.23 – 7.06 (m, 5H), 5.60-5.5 (m, 1H), 5.04 (d, J = 10.1 Hz, 1H), 4.92 (d, J = 16.9 Hz, 1H), 4.35 (s, 3H), 4.30-4.25 (m, 2H), 3.68 (s, 2H), 3.08-3.03 (m, 1H), 2.78-2.73 (m, 1H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.6, 158.3, 144.4, 135.7, 130.1, 129.4, 128.6, 128.0, 127.5, 121.6, 63.0, 60.1, 48.0, 42.4, 35.6, 14.0; HRMS-ESI (m/z) calculated for C₂₀H₂₄NO₂S⁺ [M-BF₄⁻]⁺ 342.1522, found.342.1523.

4-(1-ethoxy-1-oxo-2-(p-tolylthio)penta-3,4-dien-2-yl)-1-methylpyridin-1-ium tetrafluoroborate (9d)

Tols
$$CO_2Et$$

Me BF_4

9d

9d : Followed **One-pot procedure**. Reddish brown solid (71.2 mg, 78%), mp 96-98 °C; R_f 0.45 (DCM/MeOH= 30/1); ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, J = 6.2 Hz, 2H), 8.01 (d, J = 6.1 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 7.06 (d, J = 7.7 Hz, 2H), 5.73 (t, J = 6.6 Hz, 1H), 4.89-4.77 (m, 2H), 4.41 (s, 3H), 4.24 – 3.99 (m, 2H), 2.28 (s, 3H), 1.17 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 208.4, 167.7, 158.1, 144.7, 141.3, 136.9, 130.1, 128.1, 125.4, 91.8, 63.4, 62.9, 48.2, 21.3, 13.8; HRMS-ESI (m/z) calculated for $C_{20}H_{22}NO_2S^+$ [M-BF₄⁻] + 340.1366, found 340.1368.

V. Reduction reaction of product 5, 6 or 9

General Procedure⁸

To a solution of pyridinium salt **5**, **6** or **9** (1 equiv.) in MeOH: H₂O (9:1, 2.5 mL/mmol of pyridinium salt) was added NaBH₄ (3 equiv.) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then allowed to warm to room temperature over 1 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was quenched with saturated aqueous NaHCO₃. DCM (5 mL) was added and the

aqueous phase was extracted with DCM (3 × 20 mL). The combined organic extracts were washed with brine, dried over anhydrous NaSO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (PE:EA:TEA) to afford the corresponding tetrahydropyridines **10a-f**.

ethyl 1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2,2-diphenylcyclopropane

-1-carboxylate (10a)

10a: colorless oil, yield 67%; $R_f = 0.60$ (PE:EA:TEA = 5:1:0.02); 1H NMR (400 MHz, CDCl₃) δ 7.42 – 7.34 (m, 2H), 7.29 (s, 2H), 7.25 – 7.20 (m, 1H), 7.20 – 7.09 (m, 5H), 5.72 – 5.59 (m, 1H), 3.96 – 3.82 (m, 1H), 3.82 – 3.65 (m, 1H), 3.15-3.10 (m, 1H), 2.84 – 2.61 (m, 2H), 2.51-2.46 (m, 1H), 2.37 (d, J = 5.5 Hz, 1H), 2.24 (d, J = 5.5 Hz, 1H), 2.21 (s, 3H), 1.72 – 1.54 (m, 2H), 0.96 (t, J = 7.1 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 170.9, 141.8, 139.2, 132.0, 130.3, 128.7, 128.2, 127.6, 126.9, 126.4, 126.3, 60.8, 54.4, 51.8, 45.2, 43.8, 43.3, 29.4, 22.4, 13.8; HRMS-ESI (m/z) calculated for $C_{24}H_{28}NO_2^+$ [M+H] $^+$ 362.2115, found 362.2123.

ethyl 2-methyl-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)

-2-phenylcyclopropane-1-carboxylate (10b)

10b: colorless oil, yield 68%; $R_f = 0.40$ (PE:EA:TEA = 5:1:0.02); 1H NMR (400 MHz, CDCl₃) δ 7.30 – 7.16 (m, 5H), 5.70 – 5.67 (m, 1H), 4.26 – 4.12 (m, 2H), 3.28 – 3.18 (m, 1H), 2.41 – 2.35 (m, 1H), 2.17 – 2.05 (m, 2H), 2.02 (s, 1H), 2.01 – 1.94 (m, 1H), 1.87 (d, J = 5.7 Hz, 1H), 1.62 (d, J = 5.7 Hz, 1H), 1.57 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 171.2, 140.8, 131.6, 127.97, 127.7, 126.51, 126.50, 61.0, 55.8, 50.6, 44.4, 41.7, 32.1, 25.0, 22.0, 21.8, 14.3. HRMS-ESI (m/z) calculated for $C_{19}H_{26}NO_2^+$ [M+H] $^+$ 300.1958, found 300.1960.


ethyl 2-methyl-1-(1-methyl-1,4,5,6-tetrahydropyridin-3-yl)

-2-phenylcyclopropane-1-carboxylate (10c)

10c: colorless oil, yield 61%; $R_f = 0.50$ (PE:EA:TEA = 5:1:0.02); 1H NMR (400 MHz, CDCl₃) δ 7.28 – 7.14 (m, 5H), 5.52 – 5.50 (m, 1H), 4.24 – 4.11 (m, 2H), 3.09 – 3.03 (m, 1H), 2.62 – 2.57 (m, 1H), 2.49 – 2.35 (m, 2H), 2.15 (s, 3H), 1.89 (d, J = 5.7 Hz, 1H), 1.62 (d, J = 5.7 Hz, 1H), 1.58 (s, 3H), 1.56 – 1.48 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 171.37, 140.68, 132.04, 127.98, 127.55, 126.31, 125.57, 60.85, 54.35, 51.75, 45.20, 42.90, 32.46, 28.97, 21.85, 21.82, 14.34. HRMS-ESI (m/z) calculated for $C_{19}H_{26}NO_2^+$ [M+H] $^+$ 300.1953, found 300.1958.

ethyl 1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-phenylcyclopropane

-1-carboxylate (10d)



10d: colorless oil, yield 76%; $R_f = 0.50$ (PE:EA:TEA = 5:1:0.02); 1H NMR (400 MHz, CDCl₃) δ 7.22 - 7.08 (m, 3H), 7.04 - 6.89 (m, 2H), 4.25 - 3.97 (m, 2H), 2.96 (d, J = 15.7 Hz, 1H), 2.86 (t, J = 8.2 Hz, 1H), 2.44 - 2.32 (m, 1H), 2.21 - 2.08 (m, 1H), 1.98 (s, 2H), 1.98 (s, 3H), 1.96 - 1.91 (m, 1H) 1.86-1.81 (m, 1H), 1.75 - 1.56 (m, 3H), 1.20 (t, J = 7.1 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 173.5, 136.3, 130.8, 128.0, 127.8, 126.9, 126.6, 61.2, 56.3, 50.96, 45.1, 36.6, 31.5, 25.5, 19.3, 14.3; HRMS-ESI (m/z) calculated for $C_{18}H_{24}NO_2^+$ [M+H] $^+$ 286.1802, found 286.1804.

ethyl 1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-2-phenylcycloprop-2-ene

-1-carboxylate (10e)

10e: colorless oil, yield 65%; $R_f = 0.60$ (PE:EA:TEA = 5:1:0.02); ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 7.2 Hz, 2H), 7.47 – 7.31 (m, 3H), 7.08 (d, J = 2.1 Hz, 1H), 5.70 (t, J = 3.4 Hz, 1H), 4.13 (q, J = 6.8 Hz, 2H), 3.20 – 2.93 (m, 2H), 2.54 – 2.27 (m, 4H), 2.36 (s, 3H), 1.22-1.18 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.42, 136.64, 129.76, 128.79, 125.99, 122.04, 117.75, 116.67, 100.98, 60.74, 56.37, 51.46, 45.65, 29.71, 25.72, 14.32; HRMS-ESI (m/z) calculated for $C_{18}H_{22}NO_2$ [M+H] + 284.1645, found

284.1647.

ethyl 2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(p-tolylthio)pent-

4-enoate (10f)

10f: colorless oil, yield 60%; $R_f = 0.60$ (PE:EA:TEA = 5:1:0.02); 1H NMR (400 MHz, CDCl₃) δ 7.24 – 7.17 (m, 2H), 7.04 (d, J = 7.7 Hz, 2H), 6.00-5.90 (m, 1H), 5.17 (t, J = 3.6 Hz, 1H), 5.09 – 5.01 (m, 2H), 4.22 – 3.99 (m, 2H), 3.02 – 2.93 (m, 1H), 2.78 – 2.70 (m, 1H), 2.61-2.57 (m, 1H), 2.47-2.35 (m, 3H), 2.27 (s, 6H), 2.12-2.05 (m, 2H), 1.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl₃) δ 171.58, 139.81, 137.95, 133.85, 132.99, 129.47, 127.60, 123.19, 118.66, 65.80, 62.01, 54.82, 52.28, 46.04, 38.11, 26.82, 21.63, 14.51; HRMS-ESI (m/z) calculated for $C_{20}H_{28}NO_{2}S$ [M+H] $^+$ 346.1835, found 346.1833.


VI. References


- (1) (a) Schareina, T.; Zapf, A.; Cotte A. *Synthesis*. **2008**, 3351-3355; (b) Sreedhar, B.; Reddy, P. S.; Reddy, M. A. *Synthesis*. **2009**, 2009(10), 1732-1738; (c) Nandi, D.; Islam, R. U.; Devi, N. *New J. Chem.* **2018**, 42(2), 812-816.
- (2) Frenette, R.; Blouin, M.; Brideau, C. *Bioorg. Med. Chem. Lett.* **2002**, *12*(20), 3009-3013.
- (3) Dey, A.; Hajra, A. Org. Lett. 2019, 21(6), 1686-1689.
- (4) Soli, E. D.; Manoso, A. S.; Patterson, M. C. J. Org. Chem. 1999, 64(9), 3171-3177.
- (5) Green, S. P.; Wheelhouse, K. M.; Payne, A. D.; Hallett, J. P.; Miller, P. W.; Bull, J. A. *Org. Proc. Res. Dev.* **2019**, *24*(1), 67-84.
- (6) Pitters, J. L. Can. J. Chem. 2011, 89, 117–121.
- (7) Sturala, J.; Bohacova, S.; Chudoba, J. J. Org. Chem. 2015, 80(5), 2676-2699.
- (8) Harawa, V.; Thorpe, T. W. J. Am. Chem. Soc. 2022, 144(46), 21088-21095.


VII. ¹H and ¹³C NMR spectra of compounds





 ^{1}H NMR (400 MHz, CDCl₃)



































































































4.4586 4.

2g-BF₄ ¹H NMR (400 MHz, CDCl₃)










2h-BF₄


¹H NMR (400 MHz, CDCl₃)

















2j-BF₄ 1H NMR (400 MHz, d₆-DMSO)


















P A G

¹H-¹H NOESY of 5a














¹H-¹H NOESY of 5b








































































 $$\rm 6a$$ $^{\rm 1}H$ NMR (400 MHz, CDCl₃)
















¹H NMR (400 MHz, CDCl₃)
























¹H NMR (400 MHz, CDCl₃)











¹**H NMR** (400 MHz, CDCl₃)

























7.7228 7.




¹H NMR (400MHz, CDCl₃)







7.7288 7.




¹H NMR (400 MHz, CDCl₃)








7.7777 7.7174 7.



10d 1H NMR (400MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)

